Skip to main content
. 2023 Aug 16;14:1250276. doi: 10.3389/fgene.2023.1250276

TABLE 1.

NBTs approved by FDA for CNS disorders *Not commercially available.

Condition Drug name Target Delivery method Manufacturer Year approved
Spinal muscular atrophy Nusinersen (Spinraza) SMN2 IT Ionis/Biogen 2016
Batten’s disease Milasen* ATXN2 IT Boston Children’s Hospital 2018
Amyotrophic lateral sclerosis Tofersem (Qalsody) SOD1 IT Ionis/Biogen 2023